Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Opioid Crisis Response: More Pressure For Treatment Drugs

Executive Summary

Sharp increases in deaths from illicit drugs (heroin and synthetic opioids) could change FDA's priorities; rather than working with drug sponsors on more tamper-deterrent formulations of pain therapies, the agency may need to devote more attention to overdose treatments like naloxone.

You may also be interested in...

Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA

FDA is reviewing Amphastar’s application for a new intranasal formulation at the same time it is reconsidering minimum pharmacokinetic standards for the opioid overdose reversal agent.

Higher Naloxone Doses Narrowly Favored By FDA Panel

Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.

COVID-19 Clinical Trial Disruptions: A Real-World Test Of De-Centralized Techniques

US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts